ESC 2021 | COVERT-MI: Colchicine Attempts to Reduce Infarct Size

Colchicine does not offer protection against myocardial injury in ST-segment elevation myocardial infarction when administered during reperfusion and in the following five days, according to the randomized study COVERT-MI. It could even generate signs of damage with 3x the amount of thrombi in the ventricle.

ESC 2021 | COVERT-MI: la colchicina intenta reducir el tamaño del infarto

The results presented at the European Society of Cardiology 2021 Congress and published in Circulation were disappointing. However, that does not question the LoDoCo2 and COLCOT studies that brought the inflammatory theory back into the table. Both focused on chronic artery disease. 

COVERT-MI, however, used a loading dose of 2 mg followed by 0.5 mg every 12 hours to treat myocardium inflammation during the acute phase of the infarction. The scenarios of these studies are completely different from each other.

This double-blind study included 192 patients with ST-segment elevation infarction referred for primary angioplasty in 10 high-complexity sites in France.

The efficacy endpoint was infarction size at five days, measured by gadolinium enhancement in magnetic resonance imaging. The difference between groups was 26 g vs. 28.4 g of mass in the left ventricle, which makes it non-significant.

After three months, ventricle mass and remodeling remained similar.


Read also: ESC 2021 | RIPCORD-2: Routine FFR Evaluation of All Epicardial Vessels During Angiography.


The unexpected was the incidence of left ventricle thrombus at five days (22.2% vs. 7.4%; p = 0.01). This finding remained similar at three months of follow-up (5.3% vs. 2%), and so did the incidence of stroke.

COVERT-MI

Original Title: Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. COVERT-MI Study Investigators.

Reference: Nathan Mewton et al. Presentado en el congreso ESC 2021 y publicado simultáneamente en Circulation. 2021 Aug 23. Online ahead of print. doi: 10.1161/CIRCULATIONAHA.121.056177. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

RODIN-CUT: Successive Cutting Balloon Technique in Calcified Lesions

Moderate or severe coronary calcification can be a marker of poor prognosis in coronary artery disease, as it significantly increases the risk of failure...

Acute Coronary Syndrome with Multivessel Disease: Best Revascularization Strategy

The gold standard treatment for acute coronary syndrome (ACS), especially acute myocardial infarction (AMI) is primary angioplasty (PCI). However, 40 to 70% of ACS...

Improved Ejection Fraction in Chronic Total Occlusion?

Chronic total occlusions (CTO) represent a significant challenge in the current clinical practice, seeing as CTO percutaneous coronary intervention (PCI) is complex and involves...

Timing in Complete Revascularization in Acute Coronary Syndrome: BIOVASC 2-Year Followup

The concept of complete revascularization (CR) has been comprehensively studied, leading to diverse approaches and debates on optimal timing.  The BIOVASC trial explored the ideal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RODIN-CUT: Successive Cutting Balloon Technique in Calcified Lesions

Moderate or severe coronary calcification can be a marker of poor prognosis in coronary artery disease, as it significantly increases the risk of failure...

Acute Coronary Syndrome with Multivessel Disease: Best Revascularization Strategy

The gold standard treatment for acute coronary syndrome (ACS), especially acute myocardial infarction (AMI) is primary angioplasty (PCI). However, 40 to 70% of ACS...

Improved Ejection Fraction in Chronic Total Occlusion?

Chronic total occlusions (CTO) represent a significant challenge in the current clinical practice, seeing as CTO percutaneous coronary intervention (PCI) is complex and involves...